Back to mobile site

Pfizer (PFE), Merck KGaA Treat First Patient in Avelumab Phase 3 in RCC Setting

April 5, 2016 8:10 AM EDT Send to a Friend
Merck KGaA, Darmstadt, Germany, and Pfizer (NYSE: PFE) announced the treatment of the first patient in a Phase III study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login